Applying Lucentis for the treatment of retinopathy of prematurity by S. V. Lesovoy, O. A. Boginskaya

Subjects: Get full text

On the efficiency of treatment of wet age-related macular degeneration with Lucentis by E. M. Kasimov, A. M. Shakhmaliyeva, B. H. Gadzhiyeva

“…The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process. …”
Get full text

EXPERIENCE OF SURGICAL TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY by O. M. Trubina, V. N. Kanyukov, A. N. Kazennov, I. A. Kazennova

Subjects: Get full text

The treatment algorithm of neovascular glaucoma. Case report by S. Yu. Anisimova, S. I. Anisimov

Subjects: Get full text

Combined modality therapy for exsudative form of age-related macular degeneration by М. V. Budzinskaya, I. V. Gurova, I. V. Schegoleva, V. B. Loschenov, S. А. Shevchik, S. G. Kuzjmin, G. N. Vorogtsov

Subjects: Get full text

Microinvasive surgery in the treatment of retinal detachment associated with an optic disk pit: 2 cases report by S. V. Sdobnokova, N. A. Troitskaya, N. Yu. Malakyan

“…First was treated by intravitreal injection of Lucentis. Woman was treated by gas tamponade as a primary procedure. …”
Get full text

Biosimilars in Retinal Diseases: A Primer by Rashmi Rawat, Rushil Kumar Saxena, Manisha Agarwal

“…Retinal disease management has witnessed remarkable advances with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), off-label bevacizumab (Avastin) and the latest molecule Brolucizumab i n the management of various retinal diseases such as diabetic macular oedema, neovascular age-related macular degeneration (AMD), and retinal vein occlusions. …”
Get full text

Signicef® (levoflaxacin 0.5%) eye drops in clinical practice by E. A. Spiridonov

“…., phacoemulsification (27 cases), extracapsular cataract extraction (40 cases), intravitreal injection/IVt of Lucentis (23 cases), abscess/phlegmon drainage (3 cases). …”
Get full text

Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy by Pearse A. Keane, Adnan Tufail, Praveen J. Patel

“…In recent years, pharmacological inhibition of vascular endothelial growth factor (VEGF), via intravitreal injection of ranibizumab (Lucentis) or bevacizumab (Avastin), has offered the first opportunity to improve visual outcomes in patients diagnosed with this disorder. …”
Get full text

Prophylaxis of Macular Edema with Intravitreal Ranibizumab in Patients with Diabetic Retinopathy after Cataract Surgery: A Pilot Study by Patricia Udaondo, Maria Garcia-Pous, Salvador Garcia-Delpech, David Salom, Manuel Diaz-Llopis

“…The purpose of this study was to evaluate the effectiveness of intravitreal ranibizumab (Lucentis, Genentech, South San Francisco, Calif, USA) combined with cataract surgery for the prevention of clinically significant macular edema (CSME) in patients with diabetic retinopathy (DR). …”
Get full text

One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study by Lars Hjelmqvist, Charlotte Lindberg, Pär Kanulf, Henrik Dahlgren, Ingrid Johansson, Annica Siewert

“…The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. …”
Get full text

Intravitreal Ranibizumab for Treatment of Posttraumatic Choroidal Neovascularization: a Case Report by A. N. Kulikov, A. Yu. Kuznetsova, N. A. Nekrash, D. S. Maltsev

“…A follow-up examination in August 2018 revealed an increase in CNV activity according to OCTA and fluorescence angiography (FAG), in connection with which intravitreal administration of ranibizumab (lucentis) was performed. Subsequently, the patient was under dynamic observation for one year. …”
Get full text

Assessment the microbial contamination rate of re-used vials of bevacizumab(Avastin) and the risk of endophthalmitis. by Zainab Taher, Maytham Hashim Neamah

“…Pegaptanib (Macugen)was the first to be approved and was followed by other agents, including ranibizumab (Lucentis, Genentech, San Francisco, Calif.), bevacizumab (Avastin, Genentech) and aflibercept (Eylea, Regeneron, Tarrytown, N.Y.). …”
Get full text

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab by Sarah Sabour-Pickett, James Loughman, John M. Nolan, Jim Stack, Konrad Pesudovs, Katherine A. Meagher, Stephen Beatty

“…To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). …”
Get full text

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2. by I. V. Vorobyova, L. G. Mikhaleva, A. S. Kochergin

“…All patients before and after intravitreal injection of an angiogenesis inhibitor ranibizumab (Lucentis, Novartis) was assessed visual acuity, macular thickness and macular morphology based on the results of OCT, the retinal sensitivity according to the data of microperimetry (MAIA). …”
Get full text

The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion by M. V. Budzinskaya, A. V. Shelankova, A. A. Plukhova, N. M. Nuriyeva, A. S. Sorokin

“…For the treatment of macular edema were used an anti-VEGF agent — ranibizumab (Lucentis) 0.05 ml (0.5 mg) manufactured by Novartis (Switzerland) or glucocorticosteroid — dexamethasone implant for intravitreal injection of 0.7 mg (Ozurdex) manufactured by Allergan Pharmaceutical Ireland (Ireland). …”
Get full text

THE ROLE OF ANTI-VEGF THERAPY IN IMPROVING THE EFFICACY OF SURGICAL TREATMENT OF SECONDARY NEOVASCULAR GLAUCOMA by Uliana Sydorchuk, Ihor Novytskyy

“…Patients underwent trabeculectomy (TE) according to our modification in 18 cases or implantation of the Ex-PRESS mini-shunt in 7 cases. Lucentis was injected intravitreally at a dose of 0.5 mg 5-7 days before surgery. …”
Get full text

Analysis of intravitreal using of anti vegf-medications for diseases of fundus accompanied by exudation and neovascularization by N. G. Zavgorodnya, I. A. Poplavska, S.L. Shevluk, D.V. Martynov

“…Pegaptanib ("Macugen") was used for the treatment of 35 patients (35 eyes), the rest (15 eyes) - ranibizumab ("Lucentis"). According to fluorescein angiography the subretinal neovascular membrane was in the stage of activity in all eyes. …”
Get full text

Impact of photodynamic therapy combined with Anti-VEGF vs. Anti-VEGF monotherapy on choriocapillaris vessel density in polypoidal choroidal vasculopathy by Po-Chin Kuo, Sheng-Min Hsu, Yi-Hsun Huang, Chun-Hsiang Chang, Yi-Sheng Chang, Jia-Horung Hung, Chun-Chieh Lai, Yu-Kuei Lee

“…Purpose: To compare the choriocapillaris vessel density between intravitreal ranibizumab (Lucentis) (IVR) plus photodynamic therapy (PDT) and intravitreal aflibercept (Eylea) (IVA) monotherapy in patients experiencing polypoidal choroidal vasculopathy (PCV). …”
Get full text

The Payload Design of the CUbesat Solar Polarimeter (CUSP), for Space Weather and Solar Flares X-Ray Polarimetry by Giovanni Lombardi, Sergio Fabiani, Ettore Del Monte, Emanuele Di Meo, Andrea Lopez, Marco Camponeschi, Marco E. Biancolini, Daniele Brienza, Immacolata Donnarumma, Silvia Natalucci, Andrea Terracciano, Emanuele Zaccagnino

Get full text